Bayer Secures FDA Accelerated Approval For HYRNUO In HER2-Mutated Non-small Cell Lung Cancer

Bayer received FDA accelerated approval for HYRNUO (sevabertinib) as a first-line treatment for adults with locally advanced or metastatic non-squamous non-small cell lung cancer. The approval creates a new commercial opportunity in oncology and is a meaningful positive catalyst for Bayer's pharmaceutical pipeline, though accelerated approval may require confirmatory clinical evidence.